A study has found that a rapid, non-invasive eye exam could potentially be used as a tool for assessing Friedreich's ataxia patients and as a biomarker in clinical trials.Read more
Experiments performed in mice and in cells taken from Friedreich's ataxia (FA) patients reveal a protein called 'GRP75' might be an effective future treatment approach.Read more
The results of the patient communications survey conducted at the 2018 Ataxia UK conference were presented in London by Ataxia UK partners Costello Medical.Read more
Study finds anti-viral drug leads to decrease in frataxin levels and may be a potential future candidate for treating Friedreich's ataxia (FA).Read more
Second trial investigating troriluzole in spinocerebellar ataxia announced by Biohaven pharmaceuticals to commence at the end of January.Read more
Results from a study conducted at the London Ataxia Centre have shown that 3 proteins which may represent new biomarkers in Friedreich's ataxia (FA).Read more
A potential therapy for Glucose transporter 1 deficiency syndrome (Glut1 DS) has produced negative results in phase 3 of its clinical trial.Read more
Results from MOXIe study reveal potential therapy for Friedreich's ataxia, omaveloxolone, is well tolerated.Read more
Ataxia UK, GoFAR, FARA US and FARA Australia are pleased to announce the date of 3rd International Ataxia Research Conference.Read more
UK researchers guaranteed funding until the end of 2020 from EU programmes even in the event of a no-deal Brexit.Read more
NHS England has included hereditary ataxia in the final draft of the National Genomic Test Directory for rare and inherited disorders and cancerRead more
Results from a phase 2 clinical trial suggest that a new therapy may improve neurological function and prevent disease progression relative to the natural course of Friedreich’s ataxia (FA).Read more
We interview PhD student Wayne Yau about life as an ataxia researcher working on an Ataxia UK funded investigation on the role of genetic DNA repair mechanisms in a range of ataxias.Read more
Omaveloxolone has recently been given an Orphan drug designation for Friedreich's ataxia the European Medicines Agency.Read more
A new placebo-controlled trail in humans, testing a novel therapy, Tak-831 for Friedreich's ataxia, has begun in America.Read more
This week results were published showing the effects of an AAV (adeno-associated virus) gene therapy in a new mouse model of Friedreich’s ataxia (FA).Read more
Biopharmaceutical company, IntraBio, has received an Orphan Drug Designation from the US Food and Drug Administration (FDA) for its lead compound (IB1000) for the treatment of spinocerebellar ataxias (SCA).Read more
The AMRC has released their expenditure statistics for 2018.Read more
Ataxia UK was represented by research officer Dr Julie Vallortigara at the World Orphan Drug Congress in Washington DC. She shares her experience about this event.Read more
Ataxia UK attended conferences in Birmingham and St Asaph to and give talks about ataxia to health and social care professionals.Read more